Airway Therapeutics is developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.
AT-100 is the novel recombinant human protein rhSP-D – an engineered version of the endogenous protein hSP-D – that reduces inflammation and infection while modulating the immune response to break the cycle of injury and inflammation.
Bronchopulmonary dysplasia is a ventilation and infection-induced respiratory disease with 200,000 very preterm infants at risk in the U.S. and Europe each year. Globally, about 2.5 million very pre-term infants are at-risk annually. BPD creates long-term lung damage that can lead to pro-longed NICU stays, a range of co-morbidities, lifelong chronic consequences and even death.
For members of the scientific/medical and investment communities,
contact us at the link below by filling out our inquiry form.